O Hospital

IN A SERIES OF DOUBLE-BLIND EXPERIMENTS TO TEST THE SOPORIFIC EFFECTIVENESS OF "MANDRIX" (250 MG. OF METHAQUALONE AND 25 MG. OF DIPHENHYDRAMINE PER TABLET), 16 17-38 YR. OLD HOSPITALIZED MALE PATIENTS SUFFERING FROM DISPARATE PSYCHIATRIC ILLNESSES AND INSOMNIA RANDOMLY CHOSE 1 OF 3 MEDICATIONS: .1 GM. PHENOBARBITAL PILLS, A PLACEBO, OR MANDRIX. AVERAGE NUMBER OF TABLETS USED DAILY WERE: .92 PHENOBARBITAL, .85 PLACEBO, AND .55 MANDRIX. A 2ND GROUP OF 13 17-81 YR. OLD MALES AND FEMALES WERE ADMINISTERED MANDRIX FOR INSOMNIA, WITHOUT CONTROLS AND INDEPENDENTLY OF THEIR PSYCHIATRIC DISORDERS OR CORRESPONDING TREATMENTS. ANALYSIS OF INSOMNIA SCALE MEASUREMENTS (E.G., DURATION OF INSOMNIA, TIME REQUIRED TO ATTAIN SLEEP, NUMBER OF SLEEP INTERRUPTIONS), AND OTHER CLINICAL DATA CONFIRMS THAT COMPARATIVELY SMALLER DOSES OF MANDRIX AND LESS TIME ARE REQUIRED TO INDUCE SLEEP IN PSYCHIATRIC SS THAN PLACEBOS OR BARBITURATES, WITH MINIMUM AFTEREFFECTS AND NO INTERFERENCE IN DREAMS. (PsycInfo Database Record (c) 2021 APA, all rights reserved)